Published in Postgrad Med J on May 01, 1994
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med (1989) 15.67
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med (1987) 13.50
Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med (1985) 11.68
Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med (1991) 8.66
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem (1983) 7.70
Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet (1992) 7.09
Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) (1988) 6.76
Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet (1993) 6.53
Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med (1993) 6.37
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol (1986) 6.27
Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med (1983) 6.00
Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J (1986) 5.89
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA (1987) 5.82
Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest (1989) 5.75
The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation (1982) 5.56
Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) (1986) 5.40
Vitamin E consumption and the risk of coronary disease in women. N Engl J Med (1993) 5.39
Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med (1993) 5.14
Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med (1984) 5.02
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J (1993) 4.28
Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med (1991) 3.86
Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet (1993) 3.72
A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA (1991) 3.67
Strategies of antioxidant defense. Eur J Biochem (1993) 3.60
The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med (1992) 3.52
Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet (1991) 3.29
Dietary reduction of serum cholesterol concentration: time to think again. BMJ (1991) 3.10
Cardiovascular health and disease in women. N Engl J Med (1993) 3.08
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med (1985) 2.99
The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med (1990) 2.85
A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med (1989) 2.79
Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med (1991) 2.77
Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med (1991) 2.68
Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest (1973) 2.65
Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens (1987) 2.59
Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA (1990) 2.45
A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med (1992) 2.40
Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci U S A (1991) 2.39
Decreased mortality in users of estrogen replacement therapy. Arch Intern Med (1991) 2.26
Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med (1986) 2.26
Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol (1989) 2.07
Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr (1991) 2.01
A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation (1990) 1.93
Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA (1988) 1.87
Oestrogens, arterial status, and postmenopausal women. Lancet (1990) 1.70
Lipid peroxidation associated with successful thrombolysis. Lancet (1990) 1.69
Reperfusion injury and its pharmacologic modification. Circulation (1989) 1.67
Deleterious effects of oxygen radicals in ischemia/reperfusion. Resolved and unresolved issues. Circulation (1989) 1.57
Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J (1992) 1.55
Reperfusion-induced arrhythmias and oxygen-derived free radicals. Studies with "anti-free radical" interventions and a free radical-generating system in the isolated perfused rat heart. Circ Res (1986) 1.52
Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation (1984) 1.41
Controlled trial of sotalol for one year after myocardial infarction. Lancet (1982) 1.32
Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation (1987) 1.25
Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction. JAMA (1989) 1.20
Abrupt propranolol withdrawal in angina pectoris: effects on platelet aggregation and exercise tolerance. Am Heart J (1978) 1.18
Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension (1991) 1.17
Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med (1981) 1.14
Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol (1987) 1.11
Oxygen free radicals and cardiac reperfusion abnormalities. Hypertension (1992) 1.03
Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol (1992) 1.02
The Scottish Heart Health Study. Dietary intake by food frequency questionnaire and odds ratios for coronary heart disease risk. II. The antioxidant vitamins and fibre. Eur J Clin Nutr (1992) 1.01
Central beta-adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs. Circ Res (1990) 1.01
Beta-blockers and primary prevention of coronary heart disease in patients with high blood pressure. JAMA (1989) 1.00
Clinical review 27: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab (1991) 0.93
Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY Study. Am J Hypertens (1991) 0.91
Detection of free radicals and cholesterol hydroperoxides in blood taken from the coronary sinus of man during percutaneous transluminal coronary angioplasty. Free Radic Res Commun (1991) 0.88
Combination of calcium channel blocker and thrombolytic therapy in acute myocardial infarction. Am Heart J (1988) 0.87
Comparison of effects on lipid metabolism of antihypertensive drugs with alpha- and beta-adrenergic antagonist properties. Am J Med (1987) 0.86
Anti-oxidants show an anti-hypertensive effect in diabetic and hypertensive subjects. Clin Sci (Lond) (1991) 0.84
Prognosis of ventricular arrhythmias in relation to sudden cardiac death: therapeutic implications. J Am Coll Cardiol (1987) 0.80
A review of calcium antagonists and atherosclerosis. J Cardiovasc Pharmacol (1990) 0.79
An increase in plasma cholesterol independent of thyroid function during long-term amiodarone therapy. A dose-dependent relationship. Ann Intern Med (1991) 0.79
The effects of beta-adrenergic blocking agents on atherosclerosis and its complications. Eur Heart J (1987) 0.78
Calcium channel blockers and ischaemic heart disease: theoretical expectations and clinical experience. Eur Heart J (1991) 0.78
Relationships among black families' cardiovascular disease risk factors. Prev Med (1991) 0.78
Free radicals, antioxidants, and endothelial cell damage after percutaneous transluminal coronary angioplasty. Coron Artery Dis (1993) 0.78
Incidence of sudden cardiac death associated with coronary artery occlusion in dogs with hypertension and left ventricular hypertrophy is reduced by chronic beta-adrenergic blockade. Circulation (1990) 0.77
tPA fast by GUSTO. Lancet (1993) 0.76
Alpha 1-blockers, their antihypertensive efficacy and effects on lipids and lipoprotein. J Hum Hypertens (1989) 0.76
Sex steroid hormone receptors in the cardiovascular system. Postgrad Med (1989) 0.76
Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists? Eur J Clin Pharmacol (1990) 0.76
Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens (1988) 0.76
Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction. Am Heart J (1990) 0.75
Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol (2001) 1.77
Efficacy of hepatitis B vaccination: knowledge among clinical medical students. BMJ (1993) 1.59
The penetration of cefpirome into the potential sites of pulmonary infection. J Antimicrob Chemother (1991) 1.13
Enhanced chemiluminescent assay for measuring the total antioxidant capacity of serum, saliva and crevicular fluid. Ann Clin Biochem (1997) 1.05
Oral rehydration of infants in a large urban U.S. medical center. J Pediatr (1985) 0.95
Uric acid as a risk factor for cardiovascular disease. QJM (2000) 0.90
Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatry (1998) 0.88
An investigation of the antioxidant activity of black tea using enhanced chemiluminescence. Free Radic Res (1997) 0.88
Anticoagulant effects of antioxidant capacity. Ann Clin Biochem (1996) 0.87
Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet (1991) 0.87
Total antioxidant capacity by enhanced chemiluminescence: contribution of urate. Ann Clin Biochem (1998) 0.86
Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. J Hum Hypertens (1994) 0.86
Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens (2010) 0.82
Antioxidant depletion during aortic aneurysm repair. Br J Surg (1996) 0.79
Antioxidant consumption during exercise in intermittent claudication. Br J Surg (1995) 0.79
The adrenergic control of lipolysis: development of tolerance to beta-2 receptor stimulation with terbutaline. Clin Chim Acta (1991) 0.78
Inhibitory effects of low-density lipoproteins from men with type II diabetes on endothelium-dependent relaxation. J Am Coll Cardiol (2000) 0.78
Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolaemia and vascular disease. Atherosclerosis (1995) 0.78
The oxidation hypothesis of atherosclerosis. Lancet (1994) 0.77
Evidence for downregulation of hypothalamic 5-hydroxytryptamine receptor function in endurance-trained athletes. Exp Physiol (1994) 0.76
Adverse change in low-density lipoprotein subfractions profile with oestrogen-only hormone replacement therapy. QJM (1996) 0.75
Position of the apex beat in childhood. Arch Dis Child (1978) 0.75
LDL oxidation and coronary atherosclerosis. Lancet (1992) 0.75
A comparison of the beta 1-selectivity of conventional metoprolol and metoprolol CR during exercise in healthy volunteers. J Clin Pharm Ther (1993) 0.75
[Enanthema fixum as side effect in the use of a combination of trimethoprim and sulfamethoxazole]. Vojnosanit Pregl (1992) 0.75
Developmental outcomes in very low birth weight infants: a six-year study. W V Med J (2001) 0.75
A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease. Drug Saf (1994) 0.75
The action of garlic upon plasma total antioxidant capacity. Biochem Soc Trans (1997) 0.75
Doctors and the public concord in their acceptance of antihypertensive drug treatment. J Hum Hypertens (2006) 0.75
Oxidative stress after thrombolysis. Lancet (1998) 0.75
Erythropoietin to treat anemia of prematurity. Ann Pharmacother (1997) 0.75
A short note on the discipline of Clinical Pharmacology. Int J Clin Pharmacol Ther (2009) 0.75
Radiological evaluation of the cardiac apex in Jamaican children. Clin Radiol (1978) 0.75